摘要
建立了LC-MS/MS法测定人血浆中尼莫地平的浓度,并研究了20名健康受试者自身对照双周期交叉口服60mg尼莫地平受试制剂和参比制剂后的药物动力学。采用C18柱,流动相为甲醇,尼群地平为内标。以选择性离子反应检测(MRM)扫描方式进行检测,监测离子质荷比(m/z)为419.3→343.1(尼莫地平)和361.0→329.0(尼群地平)。血浆样品经NaH2PO4缓冲溶液(pH12)碱化,以正己烷-二氯甲烷-异丙醇混合液萃取。血浆中尼莫地平的提取回收率为62.5%～69.9%,线性范围为0.25～100ng/ml,定量限为0.25ng/ml。
A LC-MS/MS method was established for the determination of nimodipine in human plasma. According to the random two-way cross-over design, the pharmacokinetics of 20 male volunteers after oral administration of 60mg nimodipine test capsules and reference tablets was investigated. A C18 column was used, with the mobile phase of methanol. Nitrendipine was used as internal standard. The analytes were detected in the positive ion mode and selected reaction monitoring （MRM） with m/z 419.3→343.1 （nimodipine） and 361.0→329.0 （nitrendipine）. The samples were extracted with n-hexane-dichloromethane-isopropanol after alkalized by NaH2PO4 buffer solution（pH 12）. The recoveries of nimodipine were 62.5 % - 69.9 %. The calibration curve was linear in the range of 0.25 - 100ng/ml. The limit of quantification was 0.25ng/ml.
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2008年第1期39-41,共3页
Chinese Journal of Pharmaceuticals
